Should I buy or sell Sutro Biopharma stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STRO shares. View STRO analyst ratings or view top-rated stocks .

What is Sutro Biopharma's stock price target for 2024?

7 brokerages have issued 1 year target prices for Sutro Biopharma's shares. Their STRO share price targets range from $8.00 to $18.00. On average, they anticipate the company's stock price to reach $12.57 in the next year. This suggests a possible upside of 233.5% from the stock's current price. View analysts price targets for STRO or view top-rated stocks among Wall Street analysts .

How have STRO shares performed in 2024?

Sutro Biopharma's stock was trading at $4.29 at the beginning of the year. Since then, STRO shares have decreased by 12.1% and is now trading at $3.77. View the best growth stocks for 2024 here .

When is Sutro Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our STRO earnings forecast .

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.02. The firm earned $8.52 million during the quarter, compared to analysts' expectations of $8.85 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 71.42% and a negative net margin of 69.47%.

What ETF holds Sutro Biopharma's stock?

Simplify Propel Opportunities ETF holds 120,000 shares of STRO stock, representing 0.53% of its portfolio.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com . William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE) , VBI Vaccines (VBIV) , Aldeyra Therapeutics (ALDX) , Dynavax Technologies (DVAX) , Fulcrum Therapeutics (FULC) , IDEAYA Biosciences (IDYA) , Provention Bio (PRVB) , Sorrento Therapeutics (SRNE) , Xeris Biopharma (XERS) and AbbVie (ABBV) .

When did Sutro Biopharma IPO?

Sutro Biopharma (STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:STRO

Sutro Biopharma (STRO) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free STRO Stock Alerts

$3.77

-0.03 (-0.79%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.65
▼
$3.81
50-Day Range: $3.27
▼
$5.65
52-Week Range: $2.01
▼
$6.13

Volume: 770,347 shs
Average Volume: 1.38 million shs
Market Capitalization: $235.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.57

Get Sutro Biopharma alerts:

Sutro Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 233.5% Upside
$12.57 Price Target
Short Interest: Healthy
3.86% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.70
Upright™ Environmental Score
News Sentiment: 0.67
Based on 2 Articles This Week
Insider Trading: Selling Shares
$60,925 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.18) to ($2.96) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.73 out of 5 stars

Medical Sector

53rd out of 918 stocks

Biological Products, Except Diagnostic Industry

7th out of 152 stocks

4.5

Analyst's Opinion

Consensus Rating
Sutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Sutro Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
3.86% of the outstanding shares of Sutro Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Sutro Biopharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sutro Biopharma has recently increased by 3.88%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Sutro Biopharma does not currently pay a dividend.
Dividend Growth
Sutro Biopharma does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Sutro Biopharma is -0.70.

3.2

News and Social Media Coverage

News Sentiment
Sutro Biopharma has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.
Search Interest
11 people have searched for STRO on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
MarketBeat Follows
5 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sutro Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,925.00 in company stock.
Percentage Held by Insiders
Only 6.90% of the stock of Sutro Biopharma is held by insiders.
Percentage Held by Institutions
96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sutro Biopharma are expected to grow in the coming year, from ($3.18) to ($2.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sutro Biopharma is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sutro Biopharma is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sutro Biopharma has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Sutro Biopharma Stock (NASDAQ:STRO)

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

STRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

STRO Stock News Headlines

April 17, 2024 | msn.com

Sutro Biopharma (STRO) Price Target Decreased by 6.45% to 13.15

April 17, 2024 | americanbankingnews.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Buy" by Analysts

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 3, 2024 | markets.businessinsider.com

Sutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising Pipeline

April 2, 2024 | finance.yahoo.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially

April 2, 2024 | markets.businessinsider.com

Ipsen Secures Exclusive Global Rights Of Sutro Biopharma's STRO-003 ADC In Up To $900 Mln Deal

April 2, 2024 | msn.com

Ipsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADC

April 2, 2024 | globenewswire.com

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 2, 2024 | marketwatch.com

Ipsen, Sutro Biopharma Enter Into Licensing Deal Valued at Up to $900 Mln

April 2, 2024 | globenewswire.com

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

April 1, 2024 | msn.com

Penny Stock Sutro Biopharma (NASDAQ:STRO): Intriguing Play for Biotech Investors

March 27, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)

March 27, 2024 | markets.businessinsider.com

Navigating 4 Analyst Ratings For Sutro Biopharma

March 27, 2024 | finance.yahoo.com

Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances

March 26, 2024 | finanznachrichten.de

Sutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

March 26, 2024 | markets.businessinsider.com

TD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)

March 26, 2024 | markets.businessinsider.com

Sutro Biopharma Buy Rating Affirmed on Strong Financials and Promising Clinical Pipeline

March 25, 2024 | investorplace.com

STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023

March 25, 2024 | globenewswire.com

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

February 10, 2024 | msn.com

Sutro Biopharma Expands Share Offering, Raises $129M

January 9, 2024 | markets.businessinsider.com

Sutro Biopharma: Hold Rating Maintained Amid Near-Term Uncertainties and Market Potential Ambiguities

January 6, 2024 | markets.businessinsider.com

Buy Rating Justified: Sutro Biopharma’s Luvelta Shows Promise in PROC Treatment and Beyond

January 4, 2024 | finance.yahoo.com

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

December 29, 2023 | benzinga.com

Sutro Biopharma Stock (NASDAQ:STRO) Dividends: History, Yield and Dates

December 18, 2023 | finance.yahoo.com

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

December 14, 2023 | finance.yahoo.com

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

See More Headlines

Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:STRO
CUSIP: N/A
CIK: 1382101
Web: www.sutrobio.com
Phone: (650) 392-8412
Fax: N/A
Employees: 302
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.57
High Stock Price Target: $18.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +233.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,790,000.00
Net Margins: -69.47%
Pretax Margin: -57.63%
Return on Equity: -71.42%
Return on Assets: -24.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.50
Quick Ratio: 4.50

Sales & Book Value

Annual Sales: $153.73 million
Price / Sales: 1.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.46 per share
Price / Book: 1.53

Miscellaneous

Outstanding Shares: 62,440,000
Free Float: 58,134,000
Market Cap: $235.40 million
Optionable: Optionable
Beta: 0.95

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. William J. Newell J.D. (Age 66)
CEO & Director
Comp: $1.07M
Ms. Jane Chung R.Ph. (Age 52)
President & COO
Comp: $934.64k
Dr. James R. Swartz DSc
Ph.D., Sc.D., Founder
Mr. Edward C. Albini M.B.A (Age 66)
CFO & Secretary
Comp: $596.4k
Dr. Venkatesh Srinivasan Ph.d.
Chief Technical Operations Officer
Dr. Hans-Peter Gerber Ph.D.
Chief Scientific Officer
Mr. David Pauling J.D.
M.A., General Counsel
Ms. Linda A. Fitzpatrick (Age 67)
Chief People & Communications Officer
Comp: $595.79k
Dr. Nicki Vasquez Ph.D. (Age 61)
Chief Portfolio Strategy & Alliance Officer
Dr. Anne Elizabeth Borgman-Hagey M.D. (Age 55)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STRO shares.
View STRO analyst ratings or view top-rated stocks.
What is Sutro Biopharma's stock price target for 2024?: 7 brokerages have issued 1 year target prices for Sutro Biopharma's shares. Their STRO share price targets range from $8.00 to $18.00. On average, they anticipate the company's stock price to reach $12.57 in the next year. This suggests a possible upside of 233.5% from the stock's current price.
View analysts price targets for STRO or view top-rated stocks among Wall Street analysts.
How have STRO shares performed in 2024?: Sutro Biopharma's stock was trading at $4.29 at the beginning of the year. Since then, STRO shares have decreased by 12.1% and is now trading at $3.77.
View the best growth stocks for 2024 here.
When is Sutro Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our STRO earnings forecast.
How were Sutro Biopharma's earnings last quarter?: Sutro Biopharma, Inc. (NASDAQ:STRO) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.02. The firm earned $8.52 million during the quarter, compared to analysts' expectations of $8.85 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 71.42% and a negative net margin of 69.47%.
What ETF holds Sutro Biopharma's stock?: Simplify Propel Opportunities ETF holds 120,000 shares of STRO stock, representing 0.53% of its portfolio.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?: 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Sutro Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).
When did Sutro Biopharma IPO?: Sutro Biopharma (STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
How do I buy shares of Sutro Biopharma?: Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STRO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sutro Biopharma (STRO) Stock Price, News & Analysis

Sutro Biopharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Sutro Biopharma Stock (NASDAQ:STRO)

STRO Stock Price History

STRO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

STRO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™